Determination of the reduction in gastric acidity necessary to prevent pathological oesophageal reflux in patients with gastro-oesophageal reflux disease treated with a proton pump inhibitor

Alimentary Pharmacology and Therapeutics

Volumn 17, Issue 7, 2003, Pages 955-964

  Gardner, J D ^a   Sloan, S ^b   Miner Jr , P B ^c   Robinson, M ^c  

^a Science for Organizations Inc   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^c UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OMEPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

ACIDITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; ESOPHAGUS PH; GASTROESOPHAGEAL REFLUX; HUMAN; MAJOR CLINICAL STUDY; PH MEASUREMENT; PREDICTION; PREVALENCE; PRIORITY JOURNAL; PROBABILITY; RANDOMIZED CONTROLLED TRIAL; RECEIVER OPERATING CHARACTERISTIC; STOMACH PH;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ANTI-ULCER AGENTS; BENZIMIDAZOLES; CROSS-OVER STUDIES; GASTRIC ACID; GASTROESOPHAGEAL REFLUX; HUMANS; HYDROGEN-ION CONCENTRATION; OMEPRAZOLE; PROTON PUMPS; SENSITIVITY AND SPECIFICITY;

EID: 0037392290     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2003.01532.x     Document Type: Article

References (22)

1. Dent J. Gastro-oesophageal reflux disease. Digestion 1998; 59: 433-45.
2. Robinson M. Medical management of gastroesophageal reflux disease. In: Castell DO, Richter JE. eds. The Esophagus. 3rd edn. Philadelphia: Lippincott Williams & Wilkins. 1999: 447-62.
3. Jones DB, Howden CW, Burget DW, Kerr GD, Hunt RH. Acid suppression in duodenal ulcer: a meta-analysis to define optimal dosing with antisecretory drugs. Gut 1987; 28: 1120-7.
4. Burger DW, Chiverton SG, Hunt RH. Is there an optimal degree of acid suppression for healing of duodenal ulcers? Gastroenterology 1990; 99: 345-51.
5. Bell NJV, Burget D, Howden CW, Wilkinson J, Hunt RH. Appropriate acid suppression for the management of gastroesophageal reflux disease. Digestion 1992; 51(Suppl. 1): 59-67.
6. Hunt RH. The relationship between the control of pH and healing and symptom relief in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1995; 9(Suppl. 1): 3-7.
7. Gardner JD, Rodriguez-Stanley S, Robinson M. Integrated acidity and the pathophysiology of GERD. Am J Gastroenterol 2001; 96: 1363-70.
8. Gardner JD, Perdomo C. Sloan S, et al. Integrated acidity and rabeprazole pharmacology. Aliment Pharmacol Ther 2002; 16: 455-64.
9. Gardner JD, Sloan S, Miner PB Jr, Robinson M. Meal-stimulated gastric acid secretion and integrated gastric acidity in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2003; 17: 945-953.
10. Swets JA. Measuring the accuracy of diagnostic systems. Science 1988; 240: 1285-93.
11. McNeil BJ, Keeler E, Adelstein SJ. Primer on certain elements of medical decision making. N Engl J Med 1975; 293: 211-5.
12. Hanley JA, McNeil BJ. A method of comparing the areas under a receiver operating characteristic (ROC) curve. Radiology 1982; 143: 29-36.
13. Hanley JA, McNeil BJ. The meaning and use of the area under receiver operating characteristic curves derived from the same cases. Radiology 1983; 148: 839-43.
14. Motulsky H. Interpreting laboratory tests: introduction to Bayesian thinking. In: Intuitive Biostatistics. New York: Oxford University Press. 1995: 129-39.
15. Hoffrage U, Lindsey S, Hertwig R, Gigerenzer G. Communicating statistical information. Science 2000; 290: 2261-2.
16. Schindlbeck NE, Heinrich C, Konig A, Dendorfer A, Pace F, Muller-Lissner SA. Optimal thresholds, sensitivity, and specificity of long-term pH-metry for detection of gastroesophageal reflux disease. Gastroenterology 1987; 93: 85-90.
17. Jamieson JR, Stein HJ, DeMeester TR. et al. Ambulatory 24-h oesophageal monitoring: normal values, optimal thresholds, specificity, sensitivity, and reproducibility. Am J Gastroenterol 1992; 87: 1102-11.
18. Howden CW. Clinical pharmacology of omeprazole. Clin Pharmacokinet 1991; 20: 38-49.
19. Hurlimann S, Abbuhl B, Inauen W, Halter F. Comparison of acid inhibition by either oral high-dose ranitidine or omeprazole. Aliment Pharmacol Ther 1994; 8: 193-201.
20. Hedenstrom H, Alm C, Kraft M, Grahnen A. Intragastric pH after oral administration of single doses of ranitidine effervescent tablets, omeprazole capsules and famotidine fast-dissolving tablets to fasting healthy volunteers. Aliment Pharmacol Ther 1997; 11: 1137-41.
21. Hatlebakk JG, Berstad A. Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease. Clin Pharmacokinet 1996; 31: 386-406.
22. Robertson D, Aldersley M, Shepherd H, Smith CL. Patterns of acid reflux in complicated oesophagitis. Gut 1987; 28: 1484-8.